Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of “Moderate Buy” by Brokerages

Bicycle Therapeutics plc (NASDAQ:BCYC) has earned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $40.13.

BCYC has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Stephens initiated coverage on shares of Bicycle Therapeutics in a research note on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Oppenheimer reaffirmed an “outperform” rating and set a $48.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. Finally, B. Riley downgraded shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $33.00 to $28.00 in a research note on Wednesday, August 7th.

Insider Activity at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at approximately $483,141.51. The trade was a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the transaction, the chief executive officer now owns 380,864 shares of the company’s stock, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,840 shares of company stock worth $259,128. Corporate insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Bicycle Therapeutics by 79.3% during the 3rd quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock worth $868,000 after acquiring an additional 16,958 shares in the last quarter. Jane Street Group LLC grew its holdings in Bicycle Therapeutics by 35.7% during the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after acquiring an additional 5,310 shares in the last quarter. State Street Corp grew its holdings in Bicycle Therapeutics by 233.5% during the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock worth $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock worth $20,362,000 after acquiring an additional 841,299 shares in the last quarter. Finally, HighVista Strategies LLC grew its holdings in Bicycle Therapeutics by 9.7% during the 3rd quarter. HighVista Strategies LLC now owns 139,544 shares of the company’s stock worth $3,158,000 after acquiring an additional 12,289 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Trading Down 0.2 %

NASDAQ:BCYC opened at $20.35 on Thursday. The company’s 50-day moving average price is $23.79 and its 200-day moving average price is $22.99. The company has a market cap of $967.64 million, a P/E ratio of -6.20 and a beta of 0.89. Bicycle Therapeutics has a twelve month low of $13.47 and a twelve month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. During the same period in the previous year, the firm earned ($1.26) earnings per share. Bicycle Therapeutics’s quarterly revenue was down 50.0% compared to the same quarter last year. On average, analysts expect that Bicycle Therapeutics will post -3.07 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.